Silexion Therapeutics
Clinical-stage biotechnology company developing RNA interference (siRNA) therapeutics and local extended‑release biodegradable polymer microparticle delivery systems for KRAS-driven solid tumors. Lead candidate is designed for intratumoral administration in locally advanced pancreatic cancer. The company completed Phase 1/2 clinical work with a first‑generation implant and is advancing a second‑generation siRNA‑microparticle product through preclinical studies, toxicology, GMP preparation and regulatory interactions.
Industries
Nr. of Employees
small (1-50)
Patents
RNA interference compositions targeting heat shock protein 90 and methods of use thereof
US-10006030-B2
View Details
RNA interference compositions targeting heat shock protein 90 and methods of use thereof
US-10006030-B2
View DetailsProducts
SIL‑204 (siRNA in extended‑release PLG microparticles)
Second‑generation siRNA microparticle candidate composed of chemically modified siRNA sequences targeting oncogenic KRAS mutations formulated within PLG microparticles for prolonged intratumoral release and improved tumor penetration; intended for direct intratumoral administration in KRAS‑mutant locally advanced pancreatic cancer and evaluated in preclinical models for additional KRAS‑driven tumors.
First‑generation prolonged‑release siRNA implant
Earlier biodegradable polymeric implant formulation that released siRNA locally and was evaluated in Phase 1/2 clinical studies; served as a basis for optimization to a microparticle suspension format.
SIL‑204 (siRNA in extended‑release PLG microparticles)
Second‑generation siRNA microparticle candidate composed of chemically modified siRNA sequences targeting oncogenic KRAS mutations formulated within PLG microparticles for prolonged intratumoral release and improved tumor penetration; intended for direct intratumoral administration in KRAS‑mutant locally advanced pancreatic cancer and evaluated in preclinical models for additional KRAS‑driven tumors.
First‑generation prolonged‑release siRNA implant
Earlier biodegradable polymeric implant formulation that released siRNA locally and was evaluated in Phase 1/2 clinical studies; served as a basis for optimization to a microparticle suspension format.
Expertise Areas
- RNAi therapeutics development
- Intratumoral drug delivery and extended‑release polymeric formulations
- Preclinical oncology efficacy and safety testing
- Clinical trial design and clinical operations for oncology
Key Technologies
- Small interfering RNA (siRNA) / RNA interference
- Poly(lactide‑co‑glycolide) (PLG) biodegradable microparticles
- Image‑guided endoscopic intratumoral injection
- Chemical modification of oligonucleotides (to enhance stability and penetration)
News & Updates
Summary results from a multinational Phase 2 clinical study of an extended‑release siRNA implant directed against KRAS G12D/G12V were presented, reporting a suggested overall survival advantage versus chemotherapy alone in non‑resectable localized pancreatic cancer.
Press releases and updates in 2025 reporting strong preclinical efficacy in pancreatic, colorectal and lung cancer models and cell lines, with reported high inhibition rates in vitro and orthotopic model activity.
Announcement of successful completion of two‑species toxicology studies reporting no systemic organ toxicity in advance of planned regulatory submissions.
Publication and abstract describing local prolonged siRNA delivery using a biodegradable implant and combination with chemotherapy in pancreatic cancer (Oncotarget, 2015).
Multinational Phase 2 (Protact) trial results for an extended‑release siRNA implant were presented at ESMO, reporting a suggested overall survival advantage in the treated arm versus chemotherapy alone.
Summary results from a multinational Phase 2 clinical study of an extended‑release siRNA implant directed against KRAS G12D/G12V were presented, reporting a suggested overall survival advantage versus chemotherapy alone in non‑resectable localized pancreatic cancer.
Press releases and updates in 2025 reporting strong preclinical efficacy in pancreatic, colorectal and lung cancer models and cell lines, with reported high inhibition rates in vitro and orthotopic model activity.
Announcement of successful completion of two‑species toxicology studies reporting no systemic organ toxicity in advance of planned regulatory submissions.
Publication and abstract describing local prolonged siRNA delivery using a biodegradable implant and combination with chemotherapy in pancreatic cancer (Oncotarget, 2015).
Multinational Phase 2 (Protact) trial results for an extended‑release siRNA implant were presented at ESMO, reporting a suggested overall survival advantage in the treated arm versus chemotherapy alone.